What do you think about this article?
It sounds exciting - Stopping and Starting Cancer Cell Cycle Weakens and Defeats Multiple Myeloma:
http://www.sciencedaily.com/releases/2012/06/120621141311.htm
Forums
4 posts
• Page 1 of 1
Re: PD 0332991 + right cytotoxic partner drug (bortezomib?)
This method sounds promising especially since it targets the cell cycle growth phases. Targeted therapy like this has been used with tamoxifen for breast cancer with success.
The difference here is the use of the investigational agent...pd0332991which is a "highly selective" kinase inhjbitor.
Kinase inhibitors like proteasome inhibitors have numerous functions throughout the body not just on neoplastic cells. So it will be important to learn how that impacts the proteases & kinases that are neeeded for normal cell funnctions. We have seen that the tyrosine kinase inhibitors have cardiotoxicities and lots of nasty skin effects. Which is somewhat anticipated given the high turnover rate of skin hair & nails for the cell cycle. While pd0332991 targets cyclindependent cells so its effects may not be known yet on normal cells.
Overall it does sound like targeted therapy with kinases has a therapeutic role where the beniffits could outweigh risks
The difference here is the use of the investigational agent...pd0332991which is a "highly selective" kinase inhjbitor.
Kinase inhibitors like proteasome inhibitors have numerous functions throughout the body not just on neoplastic cells. So it will be important to learn how that impacts the proteases & kinases that are neeeded for normal cell funnctions. We have seen that the tyrosine kinase inhibitors have cardiotoxicities and lots of nasty skin effects. Which is somewhat anticipated given the high turnover rate of skin hair & nails for the cell cycle. While pd0332991 targets cyclindependent cells so its effects may not be known yet on normal cells.
Overall it does sound like targeted therapy with kinases has a therapeutic role where the beniffits could outweigh risks
-
harpy
Re: PD 0332991 + right cytotoxic partner drug (bortezomib?)
When do you think this type of treatment would be available, if the benefits prove to outweigh the risks? Is the purpose of this type of treatment to prevent and stop the myeloma cells from returning?
-
Anonymous
Re: PD 0332991 + right cytotoxic partner drug (bortezomib?)
The compound PD0332991 is a cyclin dependent kinase 4/6 inhibitor developed by PD. Drs. Chen-Kiang and Niesvizky have been studying the effects of this drug in preclinical studies. They have demonstrated that it is able to synchronize myeloma cells in the cell cycle, thus sensitizing the myeloma cells to Velcade.
The study was a phase 1 clinical trial examining the tolerance and toxicity of the compound with Velcade and dexamethasone. Importantly, they also tested the schedule of the drug dosing. Based on their phase 1 clinical trial, a phase 2 study is ongoing to determine the efficacy of the combination. IF continued success is observed, phase 3 trials will be desinged and conducted with the eventual hope of identifying a new compound and drug combination that may be utilized and approved for use in myeloma
Intriguing early results, but we have some time to go before we get there.
Last note, clinical trials are an incredibly important part of gaining further insight into the disease and improving therapy in the future. It is because of clinical trials that we have drugs like Velcade and Revlimid and the newer agents soon to be approved for the treatment of myeloma (carfilzomib, pomalidomide, ... and elotuzumab ... in the future). So, please consider clinical trials in your care if available.
The study was a phase 1 clinical trial examining the tolerance and toxicity of the compound with Velcade and dexamethasone. Importantly, they also tested the schedule of the drug dosing. Based on their phase 1 clinical trial, a phase 2 study is ongoing to determine the efficacy of the combination. IF continued success is observed, phase 3 trials will be desinged and conducted with the eventual hope of identifying a new compound and drug combination that may be utilized and approved for use in myeloma
Intriguing early results, but we have some time to go before we get there.
Last note, clinical trials are an incredibly important part of gaining further insight into the disease and improving therapy in the future. It is because of clinical trials that we have drugs like Velcade and Revlimid and the newer agents soon to be approved for the treatment of myeloma (carfilzomib, pomalidomide, ... and elotuzumab ... in the future). So, please consider clinical trials in your care if available.
-
Dr. Ken Shain - Name: Ken Shain, M.D., Ph.D.
Beacon Medical Advisor
4 posts
• Page 1 of 1
Return to Treatments & Side Effects